Medicare Enrolled

Dr. Michael Overman, M.D.

Medical Oncology · Houston, TX
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Consulting-driven
1515 HOLCOMBE BLVD, Houston, TX 77030
7137926161
In practice since 2006 (19 years)
NPI: 1285726281 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Overman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Overman? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Overman

Dr. Michael Overman is a medical oncology specialist in Houston, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Overman performed 67 Medicare services across 56 unique beneficiaries.

Between the years covered by Open Payments, Dr. Overman received a total of $135,975 from 27 pharmaceutical and/or device companies across 92 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Overman is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ 67 Medicare services $135,975 industry payments

Medicare Practice Summary

Medicare Utilization ↗
67
Medicare services
Bottom 4% in TX for medical oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
56
Unique beneficiaries
$95
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Office visit, established patient, complex (40-54 min) 36 $109 $537
Office visit, established patient (30-39 min) 31 $79 $266
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$135,975
Total received (2018-2024)
Avg $19,425/year across 7 years
Top 11% in TX for medical oncology
27
Companies
92
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$102,324 (75.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$32,987 (24.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$664 (0.5%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$36,330
2023
$8,326
2022
$34,733
2021
$28,061
2020
$13,497
2019
$13,065
2018
$1,962

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Merck Sharp & Dohme LLC
$29,169
Regeneron Pharmaceuticals, Inc.
$12,239
GlaxoSmithKline, LLC.
$10,801
Novartis Pharmaceuticals Corporation
$10,117
Merck Sharp & Dohme Corporation
$10,000
Takeda Pharmaceuticals U.S.A., Inc.
$9,801
Janssen Research & Development, LLC
$5,647
E.R. Squibb & Sons, L.L.C.
$5,152
ARRAY BIOPHARMA INC
$4,725
AstraZeneca Pharmaceuticals LP
$4,609
Ipsen Biopharmaceuticals, Inc
$3,915
AbbVie Inc.
$3,850
Gilead Sciences, Inc.
$3,610
Merck KGaA
$3,375
ROCHE MOLECULAR SYSTEMS, INC.
$3,270
Sirtex Medical Inc
$2,744
Coherus Biosciences Inc.
$2,400
Bayer HealthCare Pharmaceuticals Inc.
$2,264
EISAI INC.
$2,164
Bayer Healthcare Pharmaceuticals Inc.
$1,748
Amgen Inc.
$1,650
Aurobindo Pharma USA, Inc.
$1,500
Eli Lilly and Company
$875
Genentech USA, Inc.
$237
Genentech, Inc.
$70
Incyte Corporation
$24
Stryker Corporation
$20
Top 3 companies account for 38.4% of total payments
Associated products mentioned in payments ›
AXSOS · Avastin · BRAFTOVI · FRUZAQLA · IMFINZI · JEMPERLI · Khapzory · LIBTAYO · Lenvima · MK-6482 · Nexavar · PEMAZYRE · SIR-Spheres Microspheres · Stivarga · Vectibix
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (75%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Equivalent to $202,947 per 100 Medicare services performed
Looking for a medical oncology specialist in Houston?
Compare medical oncologists in the Houston area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
185
Per 100K population
3.9
County median income
$73,104
Nearest hospital
MEMORIAL HERMANN - TEXAS MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data ✓ Medicare Util. Annual (CY lag)
Industry Payments ✓ Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Overman is a clinical cardiology specialist, with moderate Medicare volume, with consulting-driven industry engagement in the top 11% of TX peers, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Overman experienced with office visit, established patient, complex (40-54 min)?
Based on Medicare claims data, Dr. Overman performed 36 office visit, established patient, complex (40-54 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Overman receive payments from pharmaceutical companies?
Yes. Dr. Overman received a total of $135,975 from 27 companies across 92 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Overman's costs compare to other medical oncologists in Houston?
Dr. Overman's average Medicare payment per service is $95. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Overman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Medical Oncologists in Houston
Browse medical oncologists in Houston ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in TX
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in TX
Which TX medical oncologists receive the most from drug and device companies.
By company
Merck Sharp & Dohme LLC Payments to Doctors
See all physicians who received payments from Merck Sharp & Dohme LLC.
By company
Regeneron Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Pharmaceuticals, Inc.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →